- Report
- January 2024
- 156 Pages
United States
€3410EUR$3,800USD£2,935GBP
- Report
- January 2024
- 114 Pages
United States
€3140EUR$3,500USD£2,703GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €449EUR$500USD£386GBP
Anoro is a brand of respiratory drugs used to treat chronic obstructive pulmonary disease (COPD). It is a combination of two drugs, umeclidinium and vilanterol, which work together to relax the airways and reduce inflammation. Anoro is taken as an inhaler and is used to reduce symptoms such as shortness of breath, wheezing, and coughing. It is also used to prevent flare-ups of COPD.
Anoro is part of a larger market of respiratory drugs, which includes other brands such as Breo, Spiriva, and Symbicort. These drugs are used to treat a variety of respiratory conditions, including asthma, COPD, and bronchitis. They are available in both inhaler and pill form, and are often prescribed in combination with other medications.
The companies in the Anoro market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Novartis. Show Less Read more